期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 66, 期 9, 页码 6218-6238出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c02058
关键词
-
In recent years, small-molecule drugs have become essential in tumor immunotherapy. The study identified compound 1 as an EP4 antagonist hit, which showed promising antitumor immune response by blocking PGE2/EP4 signaling. Further exploration led to the discovery of compound 14, which displayed high EP4 antagonistic activity, selectivity, and favorable drug-like profiles. When administered orally, compound 14 significantly inhibited tumor growth by enhancing cytotoxic CD8+ T cell-mediated antitumor immunity.
Nowadays, small-molecule drugs have become an indispensable part of tumor immunotherapy. Accumulating evidence has indicated that specifically blocking PGE2/EP4 signaling to induce robust antitumor immune response represents an attractive immunotherapy strategy. Herein, a 2H-indazole-3-carboxamide containing compound 1 was identified as a EP4 antagonist hit by screening our in-house small-molecule library. Systematic structure- activity relationship exploration leads to the discovery of compound 14, which displayed single-nanomolar EP4 antagonistic activity in a panel of cell functional assays, high subtype selectivity, and favorable drug-like profiles. Moreover, compound 14 profoundly inhibited the up-regulation of multiple immunosuppression-related genes in macrophages. Oral administration of compound 14, either as monotherapy or in combination with an anti-PD-1 antibody, significantly impaired tumor growth via enhancing cytotoxic CD8+ T cell-mediated antitumor immunity in a syngeneic colon cancer model. Thus, these results demonstrate the potential of compound 14 as a candidate for developing novel EP4 antagonists for tumor immunotherapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据